Cutaneous involvement in multiple myeloma -: A clinicopathologic, immunohistochemical, and cytogenetic study of 8 cases

被引:75
作者
Requena, L
Kutzner, H
Palmedo, G
Calonje, E
Requena, C
Pérez, G
Pastor, MA
Sangueza, OP
机构
[1] Univ Autonoma Madrid, Fdn Jimenez Diaz, Dept Dermatol, E-28040 Madrid, Spain
[2] Dermatopathol Gemeinschaftspraxis, Friedrichshafen, Germany
[3] St Thomas Hosp, Dept Dermatopathol, St Johns Inst Dermatol, London, England
[4] Hosp Gen Univ, Dept Dermatol, Valencia, Spain
[5] Wake Forest Univ, Dept Dermatol, Winston Salem, NC 27109 USA
[6] Wake Forest Univ, Dept Pathol, Winston Salem, NC 27109 USA
关键词
B-CELL LYMPHOMA; BONE-MARROW; PLASMACYTOMAS; SKIN; PROGNOSIS;
D O I
10.1001/archderm.139.4.475
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Specific cutaneous involvement in patients with multiple myeloma (MM) is very uncommon. it usually occurs in late stages of MM as a reflection of increased tumor cell burden. We studied 8 patients with cutaneous involvement of MM without underlying bony lesions and reviewed the literature on this rare dermatologic manifestation. Design: We were particularly interested in the clinical course of patients with MM and cutaneous metastases, including survival once metastases were detected and the possible influence of various forms of therapy. Our goal was also to identify the immunoglobulin and the light-chain type in these cases, with emphasis on any possible association between a particular immunoglobulin class and cutaneous involvement, as well as the histopathologic, immunohistochemical, and cytogenetic features of the neoplastic plasma cells involving the skin. Setting: University department of dermatology, university hospital, and private practice. Patients: Medical records and biopsy specimens from 8 patients with MM and specific cutaneous lesions were reviewed. Results: Cutaneous lesions consisted of multiple erythematous or violaceous nodules or plaques with a wide anatomical distribution. Histopathologically, 2 different patterns were identified: nodular and diffuse interstitial. Neoplastic plasma cells showed atypical features, and in I case they displayed a spindle shape, giving a sarcomatoid appearance to the lesion. Immunohistochemical studies demonstrated that neoplastic plasma cells were strongly positive for CD79a, CD138, and epithelial membrane antigen, and variably positive for VS38c and CD43. In each case the immunoglobulin profile and the light-chain type expression of the neoplastic cells were the same as those identified in the serum of the patients: 5 cases were IgAlambda; 2 cases were IgGkappa; and 1 case was IgAkappa. In cases 2,3, and 4, polymerase chain reaction investigations revealed monoclonal rearrangement for IgH genes, whereas the investigations for human herpesvirus 8 and Epstein-Barr virus yielded negative results. Fluorescent in situ hybridization investigations in these 3 cases demonstrated that the cutaneous neoplastic plasma cells showed the deletion of the rb-1 (retinoblastoma) gene. Despite aggressive chemotherapy, all 8 patients died a few months after the development of cutaneous involvement. Conclusions: In our series, there was a perfect correlation of immunoglobulin and light-chain type between the serum electrophoresis and the cutaneous plasma cells. Patients with MM showed a short survival once cutaneous metastases appeared independently of the therapy. The deletion the rb-1 gene may provide prognostically relevant information to identify a high-risk subset of patients with MM.
引用
收藏
页码:475 / 486
页数:12
相关论文
共 71 条
[1]   Extramedullary facial plasmacytomas with anaplastic features - A diagnostic dilemma with implications for treatment [J].
Aboulafia, DM ;
Lee, RM ;
Hafermann, M ;
Chu, FWK ;
Fenske, M .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1998, 21 (04) :401-405
[2]   CUTANEOUS PLASMACYTOMAS IN MYELOMA - RELATIONSHIP TO TUMOR-CELL BURDEN [J].
ALBERTS, DS ;
LYNCH, P .
ARCHIVES OF DERMATOLOGY, 1978, 114 (12) :1784-1787
[3]  
ANDRY P, 1991, ANN DERMATOL VENER, V118, P887
[4]   Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma [J].
Avigdor, A ;
Raanani, P ;
Levi, I ;
Hardan, I ;
Ben-Bassat, I .
LEUKEMIA & LYMPHOMA, 2001, 42 (04) :683-+
[5]   Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: Shed syndecan-1 accumulates in fibrotic regions [J].
Bayer-Garner, IB ;
Sanderson, RD ;
Dhodapkar, MV ;
Owens, RB ;
Wilson, CS .
MODERN PATHOLOGY, 2001, 14 (10) :1052-1058
[6]   CUTANEOUS LESIONS IN MULTIPLE-MYELOMA [J].
BEEVERS, DG .
BRITISH MEDICAL JOURNAL, 1972, 4 (5835) :275-&
[7]  
Bloch B, 1910, ARCH DERMATOL SYPH-G, V99, P9
[8]   CUTANEOUS MANIFESTATIONS OF MULTIPLE MYELOMA [J].
BLUEFARB, SM .
ARCHIVES OF DERMATOLOGY, 1955, 72 (06) :506-522
[9]   EXTENSIVE CUTANEOUS PLASMACYTOMAS [J].
CARERE, R ;
STEWART, AK ;
BAILEY, D ;
BAKER, MA .
LEUKEMIA & LYMPHOMA, 1993, 10 (06) :493-495
[10]   SECONDARY CUTANEOUS PLASMACYTOMA [J].
CAVO, M ;
GOBBI, M ;
GHETTI, P ;
PATRIZI, A ;
PILERI, S ;
VAROTTI, C .
ACTA HAEMATOLOGICA, 1983, 69 (04) :287-288